XML 50 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Detail)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 102 Months Ended
Sep. 06, 2022
USD ($)
Jan. 31, 2014
USD ($)
program
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
$ / shares
Sep. 30, 2022
USD ($)
product
milestone
$ / shares
Sep. 30, 2021
USD ($)
$ / shares
Jun. 28, 2022
USD ($)
Dec. 31, 2021
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues     $ 26,460 $ 28,563 $ 84,069 $ 82,715    
Accounts receivable     4,522   4,522     $ 6,013
Decrease in research and development expense     900   900      
Increased net loss     $ 53,155 $ 47,688 $ 140,305 $ 140,801    
Increased earnings per share, diluted (in dollars per share) | $ / shares     $ (0.34) $ (0.33) $ (0.93) $ (0.98)    
Increased earnings per share, basic (in dollars per share) | $ / shares     $ (0.34) $ (0.33) $ (0.93) $ (0.98)    
Sanofi S.A.                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Number of research programs | program   2            
Revenues under agreement   $ 20,000            
Revenues     $ 0 $ (759) $ 3,260 $ 1,258 $ 13,500  
Number of products approved | product         0      
Post transition assistance period 90 days              
Expenses reimbursable through December 31, 2023 (up to) $ 7,000              
Expenses reimbursable after December 31, 2023 (up to) $ 5,300              
Sanofi S.A. | Collaboration And License Agreement                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues under agreement             20,000  
Number of milestones included in transaction price | milestone         0      
Collaborative arrangement transaction price             96,300  
Collaborative arrangement estimated reimbursable service costs             62,800  
Accounts receivable     0   $ 0     600
Deferred revenue     $ 0   $ 0     $ 1,100
Sanofi S.A. | Collaboration And License Agreement | Milestone three                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Milestone revenue receivable             $ 13,500  
Sanofi S.A. | Collaboration agreement | Change In Collaboration Agreement Scope                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues       (2,500)   (2,500)    
Increased net loss       $ 2,500   $ 2,500    
Increased earnings per share, diluted (in dollars per share) | $ / shares       $ 0.02   $ 0.02    
Increased earnings per share, basic (in dollars per share) | $ / shares       $ 0.02   $ 0.02